Apollo Global Management has entered discussions to acquire Johnson & Johnson's orthopedics division in a transaction valued near $20 billion, according to reports surfacing this week. The carve-out would mark the largest private equity medical device play since Permira and Blackstone divided Medline Industries for $34 billion in 2021, and it positions Apollo squarely in the healthcare infrastructure build-out the firm telegraphed through three prior medtech acquisitions since 2022.
J&J's orthopedics unit generates approximately $9.5 billion in annual revenue across joint reconstruction, sports medicine, and trauma implants. The division holds the number two global market position behind Stryker, with particularly strong positioning in knee and hip replacement systems sold into ambulatory surgery centers. J&J has publicly stated its intention to streamline around pharmaceuticals and its MedTech segment, which houses surgical robotics and electrophysiology. The orthopedics business, while profitable, no longer fits the company's stated focus on high-growth platforms with double-digit margin expansion potential.
For Apollo, the deal logic extends beyond simple asset accumulation. The firm has built parallel healthcare infrastructure positions through its $5.1 billion LifePoint Health take-private in 2018, its $2.85 billion acquisition of ATI Physical Therapy in 2022, and its majority stake in Cano Health's primary care network. An orthopedics platform anchors the continuum: devices feed surgical volume at LifePoint's rural hospitals, post-acute rehabilitation flows to ATI clinics, and ongoing joint monitoring creates managed care relationships Cano can monetize. Apollo's healthcare vertical now represents $47 billion in deployed capital across its Credit and Equity platforms. Adding J&J's orthopedics unit consolidates buying power with distributors, creates cross-selling into Apollo's existing acute and post-acute footprint, and provides a manufacturing base the firm can reload with contract production for smaller device startups in its venture portfolio.
The financing structure will matter. Apollo's credit arm has $631 billion in assets under management and issued $28 billion in private credit to healthcare borrowers in 2024. If Apollo self-finances the majority of the deal through its BDCs and direct lending vehicles, it effectively moves capital from the left hand to the right while collecting origination fees and interest spreads that subsidize the equity check. Competing bidders—likely Blackstone, KKR, or a consortium including a sovereign wealth partner—cannot replicate that financing advantage. J&J receives cleaner execution certainty, Apollo locks in yield on both sides of its balance sheet, and LPs in Apollo's credit funds gain exposure to a pharmaceutical-grade borrower with contractual hospital revenue and Medicare reimbursement visibility.
Watch for a formal process announcement within 60 days if Apollo's preliminary diligence clears the regulatory moat. The FTC will scrutinize vertical integration between device manufacturing and hospital ownership, but Apollo has navigated similar reviews in prior LifePoint and ATI deals. More immediately, expect competing bids from Blackstone's Life Sciences group or a strategic counteroffer from Stryker, which would gain 26% global market share in joint reconstruction by absorbing its largest competitor. If the transaction closes at $20 billion, Apollo will likely syndicate 30-40% of the equity to co-investors, following the firm's standard practice on deals exceeding $15 billion. The debt package will include $8-10 billion in senior secured loans, most of which Apollo's credit funds will retain, and a $3-4 billion mezzanine tranche sold to insurance company separate accounts that Apollo manages.
J&J has separated five major divisions since 2019, including its consumer health spin into Kenvue, which now trades at $53 billion market cap—more than double the initial projections. The orthopedics exit continues that pattern: divest stable cash flow, reinvest proceeds into oncology and immunology platforms trading at higher multiples, and let financial sponsors optimize the operations J&J no longer prioritizes. Apollo gets a revenue-generating asset with 67% exposure to U.S. Medicare reimbursement, minimal patent cliff risk, and demographic tailwinds that add 340,000 hip and knee replacements annually through 2030 as the Boomer cohort ages into peak joint failure years.
The takeaway
Apollo's $20B J&J orthopedics pursuit converts private credit firepower into strategic infrastructure, self-financing the largest medtech carve-out in three years.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.